Abstract:Aims: HER2-positive breast carcinomas are all treated with first-line anti-HER2 therapy. However, immunohistochemical and molecular profiling demonstrates significant heterogeneity among HER2-positive carcinomas. Basal-like HER2-positive breast carcinomas are poorly differentiated from pure HER2-positive breast carcinomas. Materials and methods: Seventy-five patients with HER2-positive, ER- and PR-negative breast carcinomas who received anti-HER2 based neoadjuvant therapy were retrospectively analyzed. Thirty-seven cases were classified as basal-like HER2-positive breast carcinoma with any positivity for CK5/6, and thirty-eight cases were classified as pure HER2-positive breast carcinoma with completely negativity for CK5/6. The clinicopathological features and tumor responses after neoadjuvant therapy and outcomes were analyzed. Results: Compared to non-basal HER2-positive breast carcinoma, basal-like HER2-positive breast carcinoma showed distinctive histologic features including poor differentiation and syncytial tumor cells with pushing, invasive borders and a significantly higher proportion of apocrine metaplasia. They also demonstrated significantly higher histologic grade; 18/37 (48.6%) of basal-like carcinomas were grade 3, whereas only 5/38 (13.2%) of non-basal carcinomas were grade 3 (p = 0.001), Furthermore, basal-like HER2-positive breast carcinomas were more likely to be positive or completely negative for p53 (p = 0.009), and demonstrated a higher percentage of TP53 mutation (p = 0.17). These tumors were less responsive to anti-HER2 based neoadjuvant therapy, with Miller-Payne grades 1-3 higher than pure HER2-positive breast carcinoma (25/37 [67.6%] vs 16/ 38 [42.1%]), and the percentage of grade 4-5 was lower (12/37 [32.4%] vs 22/38 [57.9%]; p = 0.027). Conclusions: Basal-like HER2-positive breast carcinoma has distinctive clinicopathological features and less histologic tumor response after neoadjuvant therapy. There is urgent need to recognize basal-like HER2-positive breast carcinoma to be treated precisely.

A Clinicopathological Study of Basal-Like Breast Carcinoma

Clinicopathological characteristics of breast basal-like carcinoma

Secretory breast carcinoma: a clinicopathological and immunophenotypic study of 15 cases with a review of the literature

Biological characterization of the basal-like subtype of invasive breast carcinoma

Features of clinical pathology and immunohistology of lymphoepithelioma-like gastric carcinoma

Clinicopathologic Analysis of Basal-Like Breast Carcinoma and Triple Negative Breast Carcinoma

Primary Squamous Cell Carcinoma of the Breast with Unusual Basal-Her2 Phenotype.

The investigation of histiocytoid breast carcinoma pathologic features and related literature review

The Clinicopathological Study of the Lymphoepithelioma-Like Carcinoma of the Breast

Clinicopathologic study of lipid-rich breast carcinoma

May metaplastic breast carcinomas be actually basal-like carcinoma? Further evidence study with its ultrastructure and survival analysis

Basaloid-squamous carcinoma of the esophagus: a clinicopathologic,immuno-histochemical and electron microscopic study

A survey of immunohistochemical biomarkers for basal-like breast cancer against a gene expression profile gold standard

Clinicopathologic Analysis of Basal Cell Carcinoma

Poor histologic tumor response after adjuvant therapy in basal-like HER2-positive breast carcinoma

Study on Clinicopathological Classification and Clinical and Pathological Characteristics in Breast Cancer

Solid Variant of Mammary Adenoid Cystic Carcinoma with Basaloid Features:A Clinicopathologic and Immunohistochemical Study

Spindle Cell/sarcomatoid Metaplastic Carcinoma of Breast:A Clinicopathologic and Immunohistochemical Analysis

Lipid-rich carcinoma of the breast clinicopathologic analysis of 17 cases.

Clinicopathological features of Luminal B-like breast cancer

Expression of markers of stem cell characteristics, epithelial-mesenchymal transition, basal-like phenotype, proliferation, and androgen receptor in metaplastic breast cancer and their prognostic impact